DualityBio Experience Unprecedented Growth and Innovation in 2025 Annual Results Discover the milestones and financial highlights of DualityBio in 2025, showcasing their ambitious advancements in innovative therapies and global collaborations.

DualityBio Experience Unprecedented Growth and Innovation in 2025 Annual Results #Hong_Kong #ADC #BioNTech #DualityBio

BioNTech shares closed over 8% in trading Friday after announcing positive Phase 3 trial results for a breast cancer drug developed with Duality Biologics.

#BNTX #BioNTech #BNTXStock #BNTXNews #BNTXStockNews #BioNTechStock #BioNTechNews #BioNTechStockNews #DualityBio #BreastCancer #CancerResearch

DualityBio's Advanced HER3 Antibody-Drug Conjugate Receives FDA Fast Track Status for Cancer Treatment DualityBio's DB-1310 HER3-targeting ADC has been granted FDA Fast Track Designation for treating advanced lung cancer, advancing cancer therapy.

DualityBio's Advanced HER3 Antibody-Drug Conjugate Receives FDA Fast Track Status for Cancer Treatment #Shanghai #United_States #Cancer_Treatment #HER3_ADC #DualityBio

DualityBio's Strategic Growth: Dr. Hua Mu Takes on Global CMO Role DualityBio has appointed Dr. Hua Mu as its Global Chief Medical Officer, a key move to enhance its clinical development and regulatory compliance efforts on the global stage.

DualityBio's Strategic Growth: Dr. Hua Mu Takes on Global CMO Role #China #Shanghai #DualityBio #Hua_Mu #Global_CMO

Dr. Hua Mu Takes the Helm as Global Chief Medical Officer at DualityBio DualityBio has appointed Dr. Hua Mu as their Global Chief Medical Officer, aiming to enhance clinical development and regulatory compliance in global operations.

Dr. Hua Mu Takes the Helm as Global Chief Medical Officer at DualityBio #China #Shanghai #Chief_Medical_Officer #DualityBio #Hua_Mu

Avenzo and DualityBio Collaborate on EGFR/HER3 Cancer Treatment License Avenzo Therapeutics has secured an exclusive global license with DualityBio to develop an innovative EGFR/HER3 antibody-drug conjugate, aiming to address various solid tumors.

Avenzo and DualityBio Collaborate on EGFR/HER3 Cancer Treatment License #USA #San_Diego #Avenzo_Therapeutics #DualityBio #EGFR/HER3

Avenzo and DualityBio Formulate Exclusive Licensing Partnership for Groundbreaking Cancer Therapeutics Avenzo Therapeutics and DualityBio have secured an exclusive global license for a novel EGFR/HER3 antibody-drug conjugate, promising innovative cancer treatments.

Avenzo and DualityBio Formulate Exclusive Licensing Partnership for Groundbreaking Cancer Therapeutics #USA #San_Diego #cancer_therapy #Avenzo_Therapeutics #DualityBio